| DC-CIK细胞治疗晚期卵巢癌的临床疗效 |
| |
| 引用本文： | 郑劼,江龙委,姚露,陆晓,杨爱珍,艾月琴,张燕,张闯,黄伟谦,高艳荣,赵华,胡建华,贾绍昌. DC-CIK细胞治疗晚期卵巢癌的临床疗效[J]. 中国肿瘤生物治疗杂志, 2016, 23(5): 682-687. DOI: 10.3872/j.issn.1007-385X.2016.05.016 |
| |
| 作者姓名： | 郑劼 江龙委 姚露 陆晓 杨爱珍 艾月琴 张燕 张闯 黄伟谦 高艳荣 赵华 胡建华 贾绍昌 |
| |
| 作者单位： | 解放军第81医院肿瘤生物治疗科,江苏南京,210001 |
| |
| 基金项目： | 南京军区医学科技创新项目资助(No.14MS052) |
| |
| 摘 要： | 目的:评价自体DC-CIK细胞治疗晚期卵巢癌患者的临床疗效和安全性.方法:采集2011年8月至2016年1月解放军第81医院肿瘤生物治疗科收治的28例Ⅳ期卵巢癌患者的PBMC,经实验室体外诱导培养获得DC和CIK细胞.DC通过卵巢癌细胞(HO-8910)裂解物致敏后与CIK细胞回输至患者体内,观察DC-CIK细胞治疗前后患者临床疗效和安全性.结果:28例晚期卵巢癌患者经DC-CIK细胞免疫治疗后,ORR为7.1％(2/28),DCR为64.3％(18/28);12、36、50个月的累积生存率分别为有75％、53％和42％.经DC-CIK细胞治疗后患者外周血CD3+ CD8+细胞比例显著升高[(23.35±7.52)％vs (29.49±8.16)％;f=-3.340,P＜0.01],CD4 +/CD8+比例显著下降[(1.61±0.84)％ vs (1.21±0.74)％;t=2.785,P＜0.05],CD3+、CD3+ CD4+、CD3-CD56+、CD4+ CD25+细胞比例及CA125、CA199、TSGF水平均无显著变化(均P＞0.05);患者治疗后均无明显不良反应.结论:DC-CIK细胞治疗可改善晚期卵巢癌患者免疫状态,提高其中远期生存率,患者无明显不良反应,安全可行.
|
| 关 键 词： | 树突状细胞 细胞因子诱导的杀伤细胞 晚期卵巢癌 细胞免疫治疗 临床疗效 |
| 收稿时间： | 2016-04-15 |
| 修稿时间： | 2016-08-14 |
Clinical efficacy of patients with advanced ovarian cancer treated with DC-CIK cytotherapy |
| |
| ZHENG Jie,JIANG Longwei,YAO Lu,LU Xiao,YANG Aizhen,AI Yueqin,ZHANG Yan,ZHANG Chuang,HUANG Weiqian,GAO Yanrong,ZHAO Hu,HU Jianhua and JIA Shaochang. Clinical efficacy of patients with advanced ovarian cancer treated with DC-CIK cytotherapy[J]. Chinses Journal of Cancer Biotherapy, 2016, 23(5): 682-687. DOI: 10.3872/j.issn.1007-385X.2016.05.016 |
| |
| Authors: | ZHENG Jie JIANG Longwei YAO Lu LU Xiao YANG Aizhen AI Yueqin ZHANG Yan ZHANG Chuang HUANG Weiqian GAO Yanrong ZHAO Hu HU Jianhua JIA Shaochang |
| |
| Affiliation: | Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China,Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China and Department of Tumor Biotherapy, the 81th Hospital of PLA, Nanjing 210001, Jiangsu, China |
| |
| Abstract: | |
| |
| Keywords: | dendritic cell (DC) cytokine-induced killer cell (CIK) advanced ovarian cancer cellular immunotherapy clinical efficacy |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤生物治疗杂志》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤生物治疗杂志》下载全文 |
|
